Showing all 7 results
CILNIDIPINE & TELMISARTAN TABLETS
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Bilayer or Co-Processed Tablet, packed exclusively in secure, high-barrier Alu-Alu blister strips to ensure the stability of the moisture-sensitive Telmisartan and light-sensitive Cilnidipine.
Active Ingredient Strength Primary Clinical Function Telmisartan USP/Ph.Eur. 40 mg The Hormonal Stabilizer: Blocks the RAAS system to provide 24-hour systemic pressure control and metabolic benefits (PPAR-gamma activation). Cilnidipine USP/Ph.Eur. 10 mg The Vascular Relaxant: Provides immediate N-type and L-type calcium channel blockade to lower peripheral resistance without edema. Excipients Meglumine / Sorbitol / Sodium Hydroxide / Magnesium Stearate / Titanium Dioxide (Opaque Coating) Solubilizer / Diluent / PH Modifier / Light Shield (Engineered specifically utilizing Alkaline Matrix Solubilization. Telmisartan requires a highly alkaline environment to dissolve, while Cilnidipine is light-sensitive. Our bilayer technology ensures each API is released at its peak kinetic window). Clindipine Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Light-Shielded Cardiovascular Tablet, packed exclusively in highly secure, opaque Alu-Alu blister strips to ensure the absolute chemical stability of the highly photosensitive active ingredient.
Active Ingredient Strength Primary Clinical Function Cilnidipine USP/Ph.Eur. 5 mg The Geriatric & Titration Anchor: The definitive starting dose utilized for elderly patients or those with mild essential hypertension to prevent sudden hypotensive episodes. Cilnidipine USP/Ph.Eur. 10 mg The Global Maintenance Standard: The standardized daily therapeutic payload utilized for the vast majority of adult patients requiring chronic 24-hour blood pressure control. Cilnidipine USP/Ph.Eur. 20 mg The Severe Refractory Macrodose: Utilized strictly for severe, uncontrolled hypertension where the 10mg dose has failed to achieve target blood pressure metrics. Excipients Microcrystalline Cellulose / Lactose Monohydrate / Croscarmellose Sodium / Hypromellose / Magnesium Stearate / Opaque Polymeric Film (Titanium Dioxide base) Diluent / Densifier / Superdisintegrant / Binder / Lubricant / Protective Light Shield (Engineered specifically utilizing a dense, titanium dioxide-heavy film coat. Cilnidipine is intensely sensitive to UV and visible light; this opaque coating guarantees 100% of the active molecule survives to reach the patient’s systemic circulation) *Pack Sizes: 10×10 Opaque Alu-Alu Blisters (Optimized specifically for strict 30-day chronic cardiology dispensing regimens).
DABIGATRAN TABLETS
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Tartaric Acid-Cored Pellet Formulation, packed exclusively in highly specialized, moisture-blocking Alu-Alu blister strips with integrated desiccants to ensure the absolute chemical survival of the intensely hygroscopic prodrug.
Active Ingredient Strength Primary Clinical Function Dabigatran Etexilate Mesylate USP/Ph.Eur. 75 mg / 110 mg The Renal & Geriatric Anchor: The strictly mandated dose reductions utilized for elderly patients (over 80 years old), patients with moderate renal impairment, or those at an elevated risk of hemorrhagic bleeding. Dabigatran Etexilate Mesylate USP/Ph.Eur. 150 mg The Cardiovascular Macrodose: The massive, globally standardized therapeutic payload required for the aggressive, daily prevention of stroke and systemic embolism in Non-Valvular Atrial Fibrillation (NVAF). Excipients Tartaric Acid (Core) / Hypromellose / Talc / Hydroxypropyl Cellulose / Dimethicone Acidic Microenvironment Generator / Polymer Binder / Glidant / Film-Coating (Engineered specifically utilizing advanced Fluid-Bed Pellet Coating. The tartaric acid core is isolated with a polymer layer, then coated with the Dabigatran API, and sealed again. This prevents the acid from prematurely degrading the drug before it reaches the patient’s stomach) *Pack Sizes: 10×10 Specialized Alu-Alu Blisters or Heavy-Gauge HDPE Bottles with Desiccant Caps (Optimized specifically for absolute moisture defense).
Ivabradine HCL Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, High-Density Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute chemical stability of the highly hygroscopic hydrochloride salt.
Active Ingredient Strength Primary Clinical Function Ivabradine (as Hydrochloride) USP/Ph.Eur. 5 mg Initiation / Titration Standard: Base therapeutic unit utilized twice daily for the safe initiation of therapy, allowing the cardiologist to monitor resting heart rate before upward titration. Ivabradine (as Hydrochloride) USP/Ph.Eur. 7.5 mg Global Maintenance Standard: High-efficacy adult maintenance dose to strictly maintain the resting heart rate between 50 and 60 beats per minute. Excipients Lactose Monohydrate / Maize Starch / Maltodextrin / Colloidal Silicon Dioxide / Magnesium Stearate / Premium Opadry Film Diluent / Binder / Glidant / Lubricant / Film-Coating (Engineered specifically using precise geometric dilution to ensure the micro-dose API is flawlessly distributed, preventing accidental bradycardia from “hot spots” in a poorly blended generic tablet) *Pack Sizes: 10×10 Blisters or Bottles of 56 (Optimized specifically for strict 28-day chronic cardiology dispensing regimens).
Phytomenadione (Vitamin K1) Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Opaque Coated Tablet, packed exclusively in highly secure, moisture-resistant, and entirely light-blocking Alu-Alu or Opaque PVC/PVDC blister strips to ensure the absolute chemical stability of the photosensitive vitamin.
Active Ingredient Strength Primary Clinical Function Phytomenadione (Vitamin K1) BP/USP 10 mg Global Clinical Standard: Base therapeutic unit for the predictable reduction of elevated INR and treatment of hypoprothrombinemia. Excipients Microcrystalline Cellulose / Lactose Monohydrate / Colloidal Silicon Dioxide / Magnesium Stearate / Titanium Dioxide Diluent / Binder / Glidant / Lubricant / Heavy Opaque Film-Coating (Engineered specifically to form an impenetrable barrier against ultraviolet and visible light degradation) *Pack Sizes: 10×10 Blisters or Bottles of 100 (Optimized specifically for high-turnover pharmacy dispensing and cardiology ward stockpiles).
Ranolazine Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Engineered Polymeric Matrix Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles to ensure the absolute stability of the modified-release polymers.
Active Ingredient Strength Primary Clinical Function Ranolazine INN/Ph.Eur. 500 mg (Extended-Release) Global Clinical Standard: Base initiation dose for chronic angina management (taken twice daily). Ranolazine INN/Ph.Eur. 1000 mg (Extended-Release) Advanced maintenance dose for severe, refractory angina requiring maximum cellular relaxation. Excipients Hypromellose (HPMC) / Methacrylic Acid Copolymer / Microcrystalline Cellulose / Magnesium Stearate Hydrophilic Polymer Matrix / Enteric Matrix / Diluent (Engineered to form a viscous gel layer that controls the strict 12-hour drug diffusion rate) *Pack Sizes: 10×10 Alu-Alu Blisters or Bottles of 60 (Optimized specifically for strict 30-day chronic cardiology dispensing regimens).
Sacubutril + Valsartan Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Engineered Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute chemical stability of the sensitive dual-molecule complex.
Active Ingredient Strength (Total Dose) Primary Clinical Function Sacubitril / Valsartan INN/Ph.Eur. 24 mg / 26 mg (50 mg Total) Starting dose for patients with severe renal impairment, hepatic impairment, or those not currently taking an ACEi/ARB. Sacubitril / Valsartan INN/Ph.Eur. 49 mg / 51 mg (100 mg Total) Standard Initiation Dose: For patients switching from standard doses of ACE inhibitors or ARBs. Sacubitril / Valsartan INN/Ph.Eur. 97 mg / 103 mg (200 mg Total) Target Maintenance Dose: Maximum adult therapy for optimal mortality reduction in heart failure. Excipients Microcrystalline Cellulose / Crospovidone / Colloidal Silicon Dioxide / Magnesium Stearate Diluent / Superdisintegrant / Glidant (Engineered for immediate gastric dissolution and synchronized dual-absorption) *Pack Sizes: 14×2 or 28-Tablet Alu-Alu Blisters (Optimized specifically for strict twice-daily chronic cardiology dispensing regimens).
